HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

ALK negative anaplastic large cell lymphoma — Clinical Guidelines

Overview

Anaplastic large cell lymphoma (ALCL) is a rare subtype of T-cell non-Hodgkin lymphoma, categorized into ALK-positive and ALK-negative variants. ALK-negative ALCL lacks the anaplastic lymphoma kinase (ALK) gene rearrangement and often presents systemically without specific genetic predispositions highlighted for ALK-positive variants 1 4 7.

Diagnosis

Clinical Presentation: Fluid collection around the peri-implant capsule in breast implant-associated cases, lymphadenopathy, and systemic symptoms 1 4.

Imaging: Chest X-ray, CT scans to identify lymphadenopathy and organ involvement 1 4.

Biopsy: Essential for diagnosis, showing CD30 positivity and ALK negativity 1 7.

Laboratory Tests: Elevated white blood cell count, specific immunophenotyping 7.

Management

First-Line Treatment: Traditionally anthracycline-based combination chemotherapy (e.g., CHOP) 7.

Brentuximab Vedotin: Effective as a single-agent therapy for upfront treatment in ALK-negative ALCL, achieving complete response 7.

Surgical Management: Complete capsulectomy and implant removal recommended in breast implant-associated cases 1 4.

Supportive Care: Management of complications such as gastrointestinal issues if associated with ALK inhibitors 3.

Special Populations

Pediatrics: Limited data; treatment often follows pediatric protocols like ALCL-99-EICNHL 8.

Comorbidities: Specific considerations for patients with genetic predispositions or those on textured implants, though direct management guidelines are sparse 1 6.

Key Recommendations

Surgical Intervention for BIA-ALCL: Immediate capsulectomy and implant removal in confirmed cases 1 (Evidence: Strong).

Consider Brentuximab Vedotin: As a viable upfront treatment option for ALK-negative ALCL 7 (Evidence: Moderate).

Enhance Awareness and Surveillance: Improve recognition and monitoring of BIA-ALCL, especially in patients with textured breast implants 1 4 (Evidence: Expert opinion).

References

1 Joks MM, Czernikiewicz K, Mazurkiewicz Ł, Joks M, Balcerzak A, Kroll-Balcerzak R et al.. Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet. Clinical lymphoma, myeloma & leukemia 2024. link 2 Noguchi Y, Asano H, Masuda R, Teshigawara Y, Go M, Kimura M et al.. Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. Oncology 2024. link 3 Huang J, Zhao Y, Cao Y, Zhang Q, Ran D, Li J et al.. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS). International journal of clinical pharmacy 2022. link 4 DeCoster RC, Lynch EB, Bonaroti AR, Webster JM, Butterfield TA, Evers BM et al.. Breast Implant-associated Anaplastic Large Cell Lymphoma: An Evidence-based Systematic Review. Annals of surgery 2021. link 5 Nelson JA, McCarthy C, Dabic S, Polanco T, Chilov M, Mehrara BJ et al.. BIA-ALCL and Textured Breast Implants: A Systematic Review of Evidence Supporting Surgical Risk Management Strategies. Plastic and reconstructive surgery 2021. link 6 Ceppi F, Ortiz R, Antillón F, Vasquez R, Gomez W, Gamboa J et al.. Anaplastic Large Cell Lymphoma in Central America: A Report From the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatric blood & cancer 2016. link 7 Oregel KZ, Everett E, Zhang X, Nagaraj G. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Expert review of anticancer therapy 2016. link 8 Ben Barak A, Elhasid R, Ben Itzhak O, Ben Arieh Y, Zaidman I, Haimi M et al.. Infant anaplastic lymphoma: case report and review of the literature. Pediatric hematology and oncology 2007. link

ALK negative anaplastic large cell lymphoma